Viromed Medical AG, a medical technology company specializing in cold plasma technology, has completed the conversion of its share capital from bearer shares to registered shares. This transition follows a resolution passed at the Annual General Meeting on July 29, 2025, with amendments to the Articles of Association entered into the commercial register on August 8, 2025, making the change effective.
The conversion process involves the deregistration of all 21,250,000 bearer shares, previously held under ISIN DE000A3MQR65, by custodian banks and Clearstream Banking AG in Frankfurt am Main on the evening of January 16, 2026, designated as the Record Day. Shareholders will receive one new registered share for each previous bearer share, each with a proportionate share capital of €1.00 and the new ISIN DE000A40VZN7. The share capital is certified in a global certificate deposited with Clearstream Banking AG, with individual certification excluded as per the Articles of Association.
Trading of the existing bearer shares concluded on January 14, 2026, with the new registered shares listed on the stock exchange under the new ISIN beginning January 15, 2026. This transition does not affect shareholders' proportional ownership in the share capital or the rights associated with their shares. Additionally, it does not restrict shareholders' ability to sell their shares, as the transfer of registered shares does not require company approval.
The shift to registered shares is significant for enhancing transparency and enabling direct communication with shareholders, which can foster greater investor confidence and engagement. For the medical technology industry, this move by Viromed Medical AG, a company focused on advancing cold plasma technology in medicine, may set a precedent for other firms seeking to improve corporate governance and shareholder relations. The company's listing on the stock exchange since October 2022 and its operations through subsidiary Viromed Medical GmbH, which distributes innovative cold plasma technology across the DACH region and beyond, underscore its commitment to growth and innovation in the healthcare sector.
This conversion aligns with Viromed's goal to further develop cold plasma technology applications in medicine, potentially driving future growth and expanding its market presence. For investors and stakeholders, the change offers clearer insight into share ownership and may facilitate more efficient corporate actions. The continuity in trading under the new ISIN ensures minimal disruption, maintaining liquidity and market access for shareholders. Overall, this transition reflects a strategic step toward strengthening Viromed's corporate structure and supporting its long-term objectives in the competitive medical technology landscape. More information about the company can be found at https://www.viromed-medical-ag.de.
